

RESEARCH

Open Access



Characterization of Transferrable Mechanisms of Quinolone Resistance (TMQR) among Quinolone-resistant *Escherichia coli* and *Klebsiella pneumoniae* causing Urinary Tract Infection in Nepalese Children

Raj Kumar Shrestha^{1*}, Ashmita Thapa¹, Dhruva Shrestha¹, Sabi Pokhrel¹, Anubhav Aryal¹, Rupika Adhikari¹, Nipun Shrestha¹, Bhim Gopal Dhoubhadel^{2,3} and Christopher M Parry^{2,4,5}

Abstract

Background Transferrable mechanisms of quinolone resistance (TMQR) can lead to fluoroquinolone non-susceptibility in addition to chromosomal mechanisms. Some evidence suggests that fluoroquinolone resistance is increasing among the pediatric population. We sought to determine the occurrence of TMQR genes among quinolone-resistant *E. coli* and *K. pneumoniae* causing urinary tract infections among Nepalese outpatient children (< 18 years) and identify molecular characteristics of TMQR-harboring isolates.

Methods We performed antimicrobial susceptibility testing, phenotypic extended-spectrum β -lactamase (ESBL) and modified carbapenem inactivation method tests, and investigated the presence of six TMQR genes (*qnrA*, *qnrB*, *qnrS*, *aac(6)-Ib-cr*, *oqxAB*, *qepA*), three ESBL genes (*bla*_{CTX-M}, *bla*_{TEM}, *bla*_{SHV}), and five carbapenemase genes (*bla*_{NDM}, *bla*_{OXA-48}, *bla*_{KPC}, *bla*_{IMP}, *bla*_{VIM}). The quinolone resistance-determining region (QRDR) of *gyrA* and *parC* were sequenced for 35 TMQR-positive isolates.

Results A total of 74/147 (50.3%) isolates were TMQR positive by multiplex PCR [*aac(6)-Ib-cr* in 48 (32.7%), *qnrB* in 23 (15.7%), *qnrS* in 18 (12.3%), *qnrA* in 1 (0.7%), and *oqxAB* in 1 (0.7%) isolate]. The median ciprofloxacin minimum inhibitory concentration of TMQR-positive isolates (64 μ g/mL) was two-fold higher than those without TMQR (32 μ g/mL) ($p=0.004$). Ser-83→Leu and Asp-87→Asn in GyrA and Ser-80→Ile in ParC were the most common QRDR mutations (23 of 35). In addition, there was a statistically significant association between TMQR and two β -lactamase genes; *bla*_{CTX-M} ($p=0.037$) and *bla*_{TEM} ($p=0.000$).

Conclusion This study suggests a high prevalence of TMQR among the quinolone-resistant *E. coli* and *K. pneumoniae* isolates causing urinary tract infection in children in this area of Nepal and an association with the carriage of ESBL gene. This is a challenge for the management of urinary infections in children. Comprehensive prospective

*Correspondence:
Raj Kumar Shrestha
shrestha.raz.np@gmail.com

Full list of author information is available at the end of the article



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

surveillance of antimicrobial resistance in these common pathogens will be necessary to devise strategies to mitigate the emergence of further resistance.

Keywords Transferrable mechanisms of quinolone resistance (TMQR), Quinolone resistance, Urinary tract infection, Children, Nepal

Background

Fluoroquinolone (FQ) antimicrobials are important in the treatment of a range of infections, including urinary tract infections (UTIs). They have a broad spectrum of activity, high bioavailability, convenient dosing regimens, and high potency [1, 2]. FQs are listed as an essential medicine by World Health Organization (WHO) [3]. Their extensive use has led to a marked increase in FQ resistance globally [4–7].

Quinolone/fluoroquinolone (Q/FQ) resistance in *Enterobacteriales* is commonly attributed to chromosomal mutations in the quinolone resistance-determining region (QRDR) of the genes encoding subunits of DNA gyrase (GyrA and GyrB) and topoisomerase IV (ParC and ParE) [8]. The reduction of Q/FQ concentration in the cytoplasm by chromosomal efflux pumps or permeability alterations also contributes to resistance [9]. Transferrable mechanisms of quinolone resistance (TMQR) can additionally confer low-level Q/FQ resistance and promote the development of full resistance [10]. TMQR determinants include seven Qnr proteins, AAC(6′)-Ib-cr (an aminoglycoside acetyltransferase), and two efflux pumps, QepA and OqxAB. Qnr proteins (QnrA, QnrB, QnrC, QnrD, QnrE, QnrS, and QnrVC) are dimeric proteins belonging to the pentapeptide repeat protein (PRP) family and protect DNA gyrase and topoisomerase IV from the action of quinolones [11]. The AAC(6′)-Ib-cr is a bifunctional variant of AAC(6′)-Ib that imparts resistance to aminoglycosides and fluoroquinolones having a piperazinyl substituent, such as ciprofloxacin and norfloxacin, via acetylation of amino nitrogen in the piperazinyl ring [11]. These diverse mechanisms can act in concert to confer non-susceptibility to Q/FQ.

As the use of FQ is restricted in children [12], the increase in FQ resistance among the pediatric population is important [13, 14]. In a recent study from our institution, 66 (41.8%) of 158 *E. coli* and 7 (23.3%) of 30 *K. pneumoniae* isolates causing UTI among children were resistant to ofloxacin [15]. Studies from tertiary care centers of Nepal focusing on pediatric UTI have reported ciprofloxacin resistance in 576 (78%) of 739 and 44 (63%) of 69 isolates, and ofloxacin resistance in 104 (62%) of 168 *E. coli* isolates [16–18]. We have investigated the occurrence of TMQR among quinolone-resistant *E. coli* and *K. pneumoniae* isolates causing UTI among children at our institution and sought to identify molecular characteristics of TMQR-harboring isolates.

Materials and methods

Study design and setting

This is a retrospective study conducted at Siddhi Memorial Hospital (SMH), Bhaktapur, Nepal. SMH is a 50-bedded secondary care maternal and pediatric hospital with 10 pediatric ICU beds, serving about 16,000 pediatric OPD visits annually. *E. coli* and *K. pneumoniae* isolates obtained from UTI patients less than 18 years old attending the outpatient department (OPD) of the hospital were included in the study. An anonymized dataset, with personal identifiers removed, containing the patient's age, sex, name of the pathogen, and the susceptibility result to nalidixic acid from June 2018 to February 2021 was retrieved from the microbiology laboratory.

Microbiological methods at the time of isolation of the isolates

Clean catch mid-stream urines were collected from children suspected of UTI as per the pediatrician's discretion as a part of routine patient diagnosis. Urine cultures were performed by semi-quantitative method on a cysteine-lactose-electrolyte deficient agar (CLED) plates which were then incubated at 37 °C for 18–24 h aerobically. Urine cultures with a growth of $\geq 10^5$ CFU/mL were considered for further processing.

The presumptive identification of the pathogens was performed by Gram stain, colony morphology, and a panel of in-house biochemical tests. Susceptibility to nalidixic acid (NA) was performed by the Kirby Bauer disk diffusion method [19]. Significant isolates were stored at -40 °C at the time of isolation.

E. coli and *K. pneumoniae* isolate resistant to NA were sub-cultured from the frozen stocks on a MacConkey agar and sheep blood agar till uniform well-isolated colonies were obtained. The investigations carried out in this study include antimicrobial susceptibility testing and molecular investigations for the detection of β -lactamases, TMQR genes, and mutations in *gyrA* and *parC*.

Antimicrobial susceptibility testing

Antimicrobial susceptibility testing (AST) of *E. coli* and *K. pneumoniae* isolates was performed by the Kirby Bauer disk diffusion method according to the CLSI guideline [19]. The antimicrobial disks used for testing were ampicillin (10 μ g) [tested only for *E. coli*], amoxicillin-clavulanic acid (20/10 μ g), piperacillin-tazobactam (100/10 μ g), cefazolin (30 μ g), cefuroxime (30 μ g).

cefixime (5 µg), cefotaxime (30 µg), ceftazidime (30 µg), cefepime (30 µg), imipenem (10 µg), ciprofloxacin (5 µg), trimethoprim sulphamethoxazole (1.25/23.75 µg), nitrofurantoin (300 µg), and amikacin (30 µg). Amoxicillin-clavulanic acid, piperacillin-tazobactam, ceftazidime, ciprofloxacin, and imipenem disks were purchased from the manufacturer Mast (Mast group Ltd, Liverpool, UK) with the remainder from HiMedia (HiMedia, India). The minimum inhibitory concentration (MIC) of ciprofloxacin was determined by E-test (0.002–32 µg/mL) (HiMedia, India), and those isolates with MIC ≥ 32 µg/mL were further tested by agar dilution method following the procedures described by CLSI [20]. An isolate was defined to display multidrug resistance (MDR) if non-susceptible to ≥ 1 agent in ≥ 3 antimicrobial categories [21]. *Escherichia coli* ATCC 25922 was used for quality control.

Nucleic acid extraction

The genomic DNA was extracted using Qiagen DNA mini kit (Qiagen, Hilden, Germany) following the procedures described by the manufacturer with the only exception that the final elution was made with 150 µl of nuclease-free water (NFW). The DNA extracts were quantified using Qubit 4 Fluorometer (Invitrogen, Thermo Fisher Scientific) following the manufacturer's recommendations.

Characterization of β-lactamases

The phenotypic determination of extended-spectrum β-lactamase (ESBL) production was first performed by a combination disc diffusion method with cefotaxime, cefotaxime-clavulanic acid, ceftazidime, and ceftazidime-clavulanic acid (D62C and D64C, Mast group Ltd, Liverpool, UK). The results were interpreted as described in the CLSI guideline [19]. DNA samples of the ESBL-positive isolates were analyzed by PCR to detect *bla*_{CTX-M} [22], *bla*_{SHV} (for *E. coli* only), and *bla*_{TEM} by the assays described elsewhere [23].

The modified carbapenem inactivation method (mCIM) was used to confirm carbapenemase production among imipenem non-susceptible isolates as described in the CLSI guideline [19]. DNA samples of these isolates were analyzed by PCR to detect *bla*_{NDM}, *bla*_{OXA-48}, *bla*_{KPC}, *bla*_{IMP} and *bla*_{VIM} using the primers published previously [24].

Escherichia coli ATCC 25922 and clinical strains confirmed to harbor *bla*_{CTX-M}, *bla*_{TEM}, and *bla*_{SHV} β-lactamase genes were used for quality control for ESBL phenotyping and genotyping. Previously characterized strains confirmed to harbor *bla*_{NDM} and *bla*_{OXA-48} were used as positive controls for mCIM. DNA extracted from the control strains was used as a positive control, and *Escherichia coli* ATCC 25922 DNA was used as a negative control in PCR assays.

Detection of TMQR genes

Previously validated multiplex PCR assay for the detection of TMQR genes was used for the detection of *qnrA*, *qnrB*, *qnrS*, *oqxAB* (reported only for *E. coli*), *qepA*, and *aac(6′)-Ib-cr* [25]. Briefly, the PCR reaction mixture of 50 µl was prepared with 25 µl of multiplex PCR master mix (2X) (Qiagen, Hilden, Germany), 5 µl of the pool of primers containing 2 µM of each primer, 5 µl of template of concentration of 20 ng/µl, and 15 µl of NFW (Ambion™ Nuclease-Free water, Invitrogen, Thermo Fisher Scientific). The PCR amplification was carried out in Veriti 96 Well Thermal Cycler (Applied Biosystems, Thermo Fisher Scientific) with 15 min of initial denaturation at 95 °C followed by 30 cycles of denaturation at 94 °C for 30 s, annealing at 63 °C for 90 s, and extension for 10 min at 72 °C. The amplification products were first resolved by gel electrophoresis (1.5%, w/v) at 100 V for 40 min and visualized in a gel documentation system (Major Science, California, USA). All PCR amplicons of *qnr* genes were sequenced and confirmed by BLAST (Basic Local Alignment Search Tool).

Detection of mutations in *gyrA* and *parC*

A convenience sample of thirty-five TMQR-positive isolates with representative ciprofloxacin's interpretive categories (susceptible, intermediate, and resistant) for *E. coli* and *K. pneumoniae* were selected for the amplification of the gene fragment covering the QRDR of the *gyrA* [26] and *parC* [27]. None of the *K. pneumoniae* isolates with a TMQR gene were susceptible to ciprofloxacin. The *gyrA* and *parC* amplicons were purified and subjected to bidirectional DNA sequencing by capillary electrophoresis (Macrogen, South Korea).

The chromatograms were visualized and processed in BioEdit software, and the sequences were then imported into MEGA11 software. In MEGA11 alignment explorer, the sequences were aligned by the ClustalW algorithm followed by codon-based nucleotide alignment. The substitutions in the QRDR of GyrA and ParC were determined by comparing the amino acid sequences of the isolates to the amino acid sequences of *E. coli* ATCC 25922 (GenBank Accession number NZ_CP032085 for *gyrA*, NZ_CP009072 for *parC*) and *Klebsiella pneumoniae* ATCC 13883 (GenBank Accession number DQ673325 for *gyrA*, KFJ75438 for *parC*).

Data analysis

The data were collected in a Microsoft Excel spreadsheet and imported to IBM SPSS Statistics for Windows v.20 (IBM Corp, Armonk, NY). A chi-squared test of independence or Fisher exact test was performed to determine whether there was a significant relationship between TMQR and other categorical variables. The difference in ciprofloxacin MIC among TMQR positive and negative

isolates was investigated by the Mann-Whitney U test. A cutoff value of ≤ 0.05 for the *P*-value was considered for statistical significance.

Results

Bacterial isolates

There were 522 unique uropathogens isolated from children with a UTI within the study period. Of the 522 isolates, there were 362 *E. coli* isolates and 74 *K. pneumoniae* isolates. Nalidixic acid resistance was present in 130/362 (35.9%) of *E. coli* and 24/74 (32.4%) of *K. pneumoniae*. Five *E. coli* and two *K. pneumoniae* isolates were not recovered in the sub-culture. The final sample size of this study was 147 isolates. The isolates included in this study were obtained from 100 female (68%) and 47 (32%) male children. The median (inter-quartile range (IQR)) age of the children was 6 (2–9) years.

Antimicrobial susceptibility

The susceptibility results are in the supplementary material (Additional file 1: Fig. 1). For *E. coli*, 116/125 (92.8%) isolates were ciprofloxacin-resistant, 8/125 (6.4%) were intermediate, and only 1/125 (0.8%) isolate was susceptible. The median (IQR) ciprofloxacin MIC was 32 (16–128) $\mu\text{g/mL}$ with values ranging from 0.25 to 512 $\mu\text{g/mL}$. The proportion of ciprofloxacin resistance, intermediate phenotype, and susceptibility among *K. pneumoniae* was 16/22 (72.7%), 5/22 (22.7%), and 1/22 (4.6%), respectively. The median (IQR) ciprofloxacin MIC for *K. pneumoniae* was 64 (0.75–128) $\mu\text{g/mL}$.

The proportion of susceptible *E. coli* was highest for nitrofurantoin (120/125, 96.0%) followed by imipenem (111/125, 88.8%) and piperacillin-tazobactam (96/125, 76.8%). *K. pneumoniae* displayed the highest susceptibility towards nitrofurantoin ($n=15/22$, 68.2%), imipenem (13/22, 59.1%), piperacillin-tazobactam and amikacin (9/22, 40.9%) (Additional file 1: Fig. 1). Overall, 96/147

(65.3%) of the isolates were ESBL positive and 137/147 (93.2%) were MDR.

Distribution of TMQR genes

Of 147 isolates, 74 were found to harbor TMQR genes (50.3%) (Tables 1 and 2). The prevalence of TMQR was slightly higher in males than females, 55.3% (26/47) vs. 48% (48/100), respectively. There were only 5 neonatal UTI cases caused by nalidixic acid-resistant organisms. Among the rest of the age groups, TMQR positivity was highest for adolescents (14/23, 60.9%) and lowest for children aged 6–12 years (24/58, 41.4%). The proportion of presence of TMQR was about 10% higher in *K. pneumoniae* (13/22, 59.1%) than in *E. coli* (61/125, 48.8%).

The different TMQR gene combinations detected are in Table 2. A gel electrophoresis picture of the PCR amplification products of the representative TMQR positive isolates is shown in the supplementary material section (Additional file 2 Fig. 2) The most frequently detected TMQR gene was *aac(6')-Ib-cr* present in 48 (32.7%) isolates. The *qnrB*, *qnrS*, *qnrA*, and *oqxAB* genes were detected in 23 (15.7%), 18 (12.3%), 1 (0.7%), and 1 (0.7%) isolate, respectively. Among 23 *qnrB* genes, 4 were *qnrB1* and the rest were *qnrB4*. All 18 *qnrS* and one *qnrA* gene were *qnrS1* and *qnrA1*, respectively. Of the 74 TMQR-positive isolates, 13 had two, and 2 had three TMQR genes. In *E. coli*, *aac(6')-Ib-cr* ($n=39$), *qnrB* ($n=16$), and *qnrS* ($n=16$) were among the most frequent, and similarly, for *K. pneumoniae* it was *aac(6')-Ib-cr* ($n=9$) and *qnrB* ($n=7$).

GyrA and ParC substitutions

The amino acid substitution profiles observed in the QRDR of GyrA and ParC of *E. coli* and *K. pneumoniae* along with ciprofloxacin MIC values and the presence of TMQR genes are presented in Table 3. Twenty of 30 *E. coli* and three of five *K. pneumoniae* isolates had double residue substitutions (Ser-83→Leu and Asp-87→Asn) in GyrA and single substitution in ParC (Ser-80→Ile). Three *E. coli* isolates had double mutations in ParC (Ser-80→Ile and Glu-84→Val) in addition to GyrA double mutations (Ser-83→Leu and Asp-87→Asn). One *E. coli* isolate also had double-double mutations, but the alteration at the 84th position in ParC was from glutamic acid to glycine (Glu-84→Gly). One *K. pneumoniae* isolate had an alteration from aspartic acid to glycine at the 87th position in addition to Ser-83→Tyr in GyrA and Ser-80→Ile in ParC.

Co-existence of TMQR with β -lactamase genes

The combinations of TMQR genes with β -lactamases are presented in Table 2. Among 74 TMQR-positive isolates, *bla*_{CTX-M}, *bla*_{TEM}, and *bla*_{SHV} were found in 51 (68.9%), 35 (47.3%), and 1 (1.4%) isolates, respectively. Four *K. pneumoniae* and twenty-five *E. coli* that harbored TMQR

Table 1 Proportion of TMQR positivity stratified by sex, age groups, and pathogens

Variables	TMQR (%)	
	Negative	Positive
Sex		
Male	21 (44.7)	26 (55.3)
Female	52 (52.0)	48 (48.0)
Age groups		
Neonates (0–28 days)	1 (20.0)	4 (80.0)
Infants (1 month–2 years)	17 (44.7)	21 (55.3)
Preschool (3–5 years)	12 (52.2)	11 (47.8)
Children (6–12 years)	34 (58.6)	24 (41.4)
Adolescents (13–17 years)	9 (39.1)	14 (60.9)
Organism		
<i>Escherichia coli</i>	64 (52.2)	61 (48.8)
<i>Klebsiella pneumoniae</i>	9 (40.9)	13 (59.1)

Table 2 Co-occurrence of transferrable mechanisms of quinolone resistance determinants with β -lactamase gene combinations

TMQR-positive		
TMQR genes	ESBL or β -lactamase genes	Carbapen-emase genes
<i>qnrB</i> (n=9)		
<i>qnrB4</i> (n=3)		
<i>qnrB1</i> (n=1)	<i>bla</i> _{CTX-M}	
<i>qnrB1</i> (n=1)	<i>bla</i> _{CTX-M} <i>bla</i> _{TEM}	
<i>qnrB4</i> (n=2)	<i>bla</i> _{CTX-M} <i>bla</i> _{TEM}	
<i>qnrB4</i> (n=2)		<i>bla</i> _{OXA-48}
<i>qnrS</i> (n=15)		
<i>qnrS1</i> (n=2)		
<i>qnrS1</i> (n=3)	<i>bla</i> _{CTX-M}	
<i>qnrS1</i> (n=7)	<i>bla</i> _{CTX-M} <i>bla</i> _{TEM}	
<i>qnrS1</i> (n=1)	<i>bla</i> _{CTX-M}	<i>bla</i> _{OXA-48}
<i>qnrS1</i> (n=2)		<i>bla</i> _{OXA-48}
<i>aac(6)-Ib-cr</i> (n=35)		
<i>aac(6)-Ib-cr</i> (n=2)		
<i>aac(6)-Ib-cr</i> (n=10)	<i>bla</i> _{CTX-M}	
<i>aac(6)-Ib-cr</i> (n=5)	<i>bla</i> _{TEM}	
<i>aac(6)-Ib-cr</i> (n=12)	<i>bla</i> _{CTX-M} <i>bla</i> _{TEM}	
<i>aac(6)-Ib-cr</i> (n=1)	<i>bla</i> _{CTX-M} <i>bla</i> _{SHV}	
<i>aac(6)-Ib-cr</i> (n=1)	<i>bla</i> _{TEM}	<i>bla</i> _{NDM} <i>bla</i> _{OXA-48}
<i>aac(6)-Ib-cr</i> (n=3)		<i>bla</i> _{NDM}
<i>aac(6)-Ib-cr</i> (n=1)		<i>bla</i> _{NDM} <i>bla</i> _{OXA-48}
<i>qnrS1, qnrB4</i> (n=1)		
<i>oqxAB, qnrS1</i> (n=1)	<i>bla</i> _{CTX-M}	
<i>aac(6)-Ib-cr, qnrB</i> (n=11)		
<i>aac(6)-Ib-cr, qnrB1</i> (n=1)	<i>bla</i> _{CTX-M}	
<i>aac(6)-Ib-cr, qnrB4</i> (n=1)	<i>bla</i> _{CTX-M}	
<i>aac(6)-Ib-cr, qnrB4</i> (n=5)	<i>bla</i> _{CTX-M} <i>bla</i> _{TEM}	
<i>aac(6)-Ib-cr, qnrB4</i> (n=1)	<i>bla</i> _{CTX-M}	<i>bla</i> _{NDM}
<i>aac(6)-Ib-cr, qnrB4</i> (n=1)	<i>bla</i> _{CTX-M}	<i>bla</i> _{OXA-48}
<i>aac(6)-Ib-cr, qnrB4</i> (n=1)	<i>bla</i> _{CTX-M} <i>bla</i> _{TEM}	<i>bla</i> _{OXA-48}
<i>aac(6)-Ib-cr, qnrB1</i> (n=1)		<i>bla</i> _{NDM}
<i>aac(6)-Ib-cr, qnrB4, qnrS1</i> (n=1)	<i>bla</i> _{CTX-M} <i>bla</i> _{TEM}	
<i>aac(6)-Ib-cr, qnrB4, qnrA1</i> (n=1)	<i>bla</i> _{CTX-M}	
TMQR-negative		
Number (n)	ESBL or β -lactamase genes	Carbapen-emase genes
n=36	<i>bla</i> _{CTX-M}	
n=1	<i>bla</i> _{SHV}	
n=1	<i>bla</i> _{TEM}	
n=1	<i>bla</i> _{CTX-M}	<i>bla</i> _{NDM} <i>bla</i> _{OXA-48}
n=3		<i>bla</i> _{OXA-48}
n=2		<i>bla</i> _{NDM}
n=1		<i>bla</i> _{NDM} <i>bla</i> _{OXA-48}

had both *bla*_{CTX-M} and *bla*_{TEM}. A statistically significant association of TMQR positivity was observed with ESBL phenotype (p=0.005) and the presence of *bla*_{CTX-M}

(p=0.037) and *bla*_{TEM} (p=0.000) (Additional file 3: Table 1).

Of 23 imipenem non-susceptible isolates, carbapenemase production was observed in 21 isolates by mCIM. The proportion of *bla*_{OXA-48} and *bla*_{NDM} among TMQR positive and negative isolates were 12.2% (9 of 74) vs. 6.8% (5 of 73) and 9.5% (7 of 74) vs. 5.5% (4 of 73), respectively. This association was not statistically significant (Additional file 3: Table 1). No isolate was found to be positive for *bla*_{KPC}, *bla*_{IMP} and *bla*_{VIM}.

Discussion

This study demonstrates alarmingly high levels of FQ resistance among *E. coli* and *K. pneumoniae* isolates causing UTI in children attending the outpatient department of Siddhi Memorial Hospital, Bhaktapur, Nepal. Half of the isolates were TMQR positive which suggests that TMQR genes may have an important role in the emergence of quinolone resistance in *E. coli* and *K. pneumoniae* isolates within our study population. TMQR genes were found to have a statistically significant association with two β -lactamases, *bla*_{CTX-M} and *bla*_{TEM}.

We found a high prevalence of TMQR in diverse gene combinations among study isolates. Similar high proportions of the TMQR genes have been reported in previous studies, while few studies have comparatively lower proportions. The proportion of TMQR positivity among FQ-resistant isolates we report, 68/132 (51.5%) of ciprofloxacin-resistant isolates, is similar to a study from the Netherlands (29/ 56, 51.8%) [28], higher than in Korea (13/122, 10.7%) [29], Taiwan (37/248, 14.9%) [30], and China (137/302, 45.4%) [31], and lower than in Iran (54/60, 90%) [32], South Africa (47/48, 98%) [33], and Egypt (90/90, 100%) [34]. Studies from China, Korea, and Taiwan investigated solely the *E. coli* isolates and the Iran study included *E. coli* and *K. pneumoniae*. The rest of the three studies had various *Enterobacteriales* isolates. The proportion and distribution of TMQR genes vary among different studies possibly due to the heterogeneity in the isolate selection criteria, the specific TMQR genes investigated, and the study population. Also, the actual proportion of TMQR could be slightly higher than reported in this study among uropathogens at our institution because they can be present even among nalidixic acid-susceptible *Enterobacteriales* [11]. Since we only included nalidixic-resistant isolates, we might have missed isolates with such phenotype.

The distribution of the TMQR genes observed in this study is consistent with the general distribution reported by previous studies. We found the highest prevalence for three TMQR genes; *aac(6)-Ib-cr* (n=48, 32.7%), *qnrB* (n=23, 15.7%), and *qnrS* (n=18, 12.3%) (Table 2). In line with this study, the *aac(6)-Ib-cr* gene was the most common TMQR gene among FQ-resistant *E. coli*

Table 3 Distribution of GyrA and ParC substitutions in 30 *E. coli* and 5 *K. pneumoniae* isolates

Organism	Isolate	Ciprofloxacin MIC (µl/mL)	TMQR	Amino acid residue substitutions in QRDR			
				GyrA		ParC	
				Ser-83	Asp-87	Ser-80	Glu-84
<i>E. coli</i>	EC147	0.25	<i>qnrS1</i>	-	-	-	-
	EC112	0.5	<i>qnrS1</i>	-	-	-	-
	EC49	0.5	<i>qnrS1</i>	-	-	-	-
	EC145	2	<i>qnrS1</i>	Leu	Asn	-	-
	EC114	2	<i>qnrS1</i>	Leu	-	-	-
	EC45	3	<i>qnrS1</i>	Leu	-	-	-
	EC35	16	<i>qnrS1</i>	Leu	Asn	Ile	-
	EC99	32	<i>aac(6')-Ib-cr, qnrS1, qnrB4</i>	Leu	Asn	Ile	-
	EC142	32	<i>qnrS1</i>	Leu	Asn	Ile	-
	EC121	32	<i>aac(6')-Ib-cr</i>	Leu	Asn	Ile	Val
	EC5	64	<i>qnrB4</i>	Leu	Asn	Ile	-
	EC66	64	<i>qnrB4</i>	Leu	Asn	Ile	-
	EC91	64	<i>aac(6')-Ib-cr</i>	Leu	Asn	Ile	-
	EC64	64	<i>aac(6')-Ib-cr</i>	Leu	Asn	Ile	-
	EC104	64	<i>qnrB4</i>	Leu	Asn	Ile	-
	EC43	64	<i>aac(6')-Ib-cr</i>	Leu	Asn	Ile	-
	EC69	64	<i>acc(6')-Ib-cr</i>	Leu	Asn	Ile	-
	EC76	128	<i>qnrB4</i>	Leu	Asn	Ile	-
	EC115	128	<i>aac(6')-Ib-cr</i>	Leu	Asn	Ile	-
	EC139	128	<i>aac(6')-Ib-cr, qnrB4</i>	Leu	Asn	Ile	-
	EC124	128	<i>qnrS1</i>	Leu	Asn	Ile	-
	EC108	128	<i>aac(6')-Ib-cr</i>	Leu	Asn	Ile	Val
	EC134	128	<i>qnrB1</i>	Leu	Asn	Ile	-
	EC56	128	<i>aac(6')-Ib-cr</i>	Leu	Asn	Ile	-
	EC67	256	<i>aac(6')-Ib-cr</i>	Leu	Asn	Ile	-
EC74	256	<i>aac(6')-Ib-cr, qnrB4</i>	Leu	Asn	Ile	-	
EC46	256	<i>aac(6')-Ib-cr, qnrB4</i>	Leu	Asn	Ile	Val	
EC12	256	<i>aac(6')-Ib-cr</i>	Leu	Asn	Ile	Gly	
EC53	256	<i>aac(6')-Ib-cr, qnrB4</i>	Leu	Asn	Ile	-	
EC125	512	<i>qnrB4</i>	Leu	Asn	Ile	-	
<i>K. pneumoniae</i>	KP97	0.5	<i>qnrS1</i>	-	-	-	-
	KP146	64	<i>qnrB1</i>	Tyr	Gly	Ile	-
	KP41	128	<i>aac(6')-Ib-cr, qnrB4</i>	Leu	Asn	Ile	-
	KP3	128	<i>aac(6')-Ib-cr</i>	Leu	Asn	Ile	-
	KP40	256	<i>aac(6')-Ib-cr, qnrB4</i>	Leu	Asn	Ile	-

Note: Ser=Serine, Leu=Leucine, Asp=Aspartic acid, Asn=Asparagine, Gly=Glycine, Ile=Isoleucine, Glu=Glutamic acid, Val=Valine, Tyr=Tyrosine. "-" represents wild type (i.e. no substitution)

in the investigation in South Korea (11/122, 9%) [29], China (74/302, 24.5%) [31], and Netherlands (23/56, 41.1%) [28]. Studies from Iran, South Africa, China, Taiwan, and Egypt found *qnrB* and *qnrS* as the most common compared to other *qnr* genes investigated among FQ-resistant clinical isolates, in agreement with our findings [30–34]. On the other hand, the prevalence of *oqxAB* or *oqxA/B* in Iran [*oqxA*: 22/60 (36.7%), *oqxB*: 31/60 (51.7%)], South Africa [*oqxA*: 20/48 (41.7%), *oqxB*: 43/48 (89.6%)], China [*oqxAB*: 19/302 (6.3%)], and Taiwan [*oqxAB*: 15/248 (6.1%)] is contrary to our findings; we only found one *E. coli* isolate with *oqxAB* gene among

125 isolates investigated [30–33]. No isolate was found to harbor *qepA* gene similar to the study in the Netherlands and Taiwan [28, 30], but 3/60 (5.0%), 9/90 (10.0%), and 36/302 (11.9%) of FQ-resistant isolates were found to possess *qepA* in Iran, Egypt, and China, respectively [31, 32, 34]. Overall, our data in conjunction with the previous findings suggest that *aac(6')-Ib-cr* and the two *qnr* genes, *qnrB* and *qnrS*, are the most prevalent TMQR genes among Q/FQ-resistant *Enterobacteriales* in general. A recent study demonstrated that possession of *aac(6')-Ib-cr* gives a selective advantage to *E. coli* ST131 in the presence of ciprofloxacin [35]. In addition, alone or in

combination with chromosomal mutations, QnrS1 has been shown to increase bacterial fitness while QnrA1 and QepA2 decrease fitness [11]. These observations could explain the predominance of *aac(6′)-Ib-cr* and *qnrS*, and the low prevalence of *qnrA* and *qepA*.

Our data show that TMQR-positive isolates have higher FQ MIC than those that lack them similar to studies from Iran and Korea [36, 37]. The ciprofloxacin MIC values were significantly higher in TMQR positive isolates (Median=64 µg/mL, n=74) compared to TMQR negative isolates (Median=32 µg/mL, n=73) (Mann-Whitney U=1969, Z=-2.871, p=0.004, but with a small effect size of r=0.24). Results from the analysis of 35 representative isolates suggest that the concomitant presence of GyrA and ParC substitutions accompanies TMQR genes to result in high levels of FQ resistance (Table 3). Similar findings of multiple substitutions in GyrA and ParC along with TMQR genes leading to high FQ resistance have been shown in other studies [34, 38].

The statistically significant association of TMQR with ESBL observed in this study mirrors previous findings from several other studies [36, 37, 39, 40]. The β-lactamase genotypes, *bla*_{TEM} and *bla*_{CTX-M}, showed an independent association with TMQR, but the difference in the proportion of *bla*_{TEM} was remarkably high between TMQR positive and TMQR negative group (47.3% vs. 1.4%) (Additional file 3: Table 1). Notably, of 57 ESBL-producing TMQR positive isolates, 29 (50.9%) co-harbored both *bla*_{TEM} and *bla*_{CTX-M} while no TMQR negative isolate had more than one β-lactamase gene (Table 2). These observations suggest that the association of β-lactamase and TMQR is driven by the co-existence of multiple β-lactamase genes rather than a single genotype in the study population. In a study from Iran investigating UTI caused by *Enterobacteriales*, 72 (43.6%) isolates had the co-existence of *bla*_{CTX-M} and *bla*_{TEM} among 165 ESBL-producing TMQR positive *E. coli* and *K. pneumoniae* isolates [36]. In contrast, among 155 ESBL-positive TMQR harboring *K. pneumoniae* (originating from various clinical specimens) in a study in Algeria, all 155 isolates had *bla*_{CTX-M} only [41]. Geographic, demographic, and differences in clinical specimens could account for this disparity. The predominance of *bla*_{CTX-M} as the most common ESBL gene associated with TMQR is in an agreement with both Iranian and Algerian studies. We also demonstrate carbapenemase genes among TMQR-positive isolates, in contrast to previous findings; most studies either had no or negligible TMQR-positive isolate resistant to carbapenem [31, 34, 39, 42]. Two-thirds (14/21, 66.7%) of the carbapenemase-producing isolates were TMQR-positive. Although, this was not a statistically significant association (Additional file 3: Table 1).

WHO's GLASS report 2022 showed that more than 90% of antimicrobial use in Nepal in 2018 was attributed to oral administration reflecting their use in the community setting [43]. Ciprofloxacin and cefixime were the second and third most consumed oral antimicrobials, respectively. Pathogens harboring resistance mechanisms for either or both of these two antimicrobials most likely thrived under such high selective pressure in the community. A recent study from a tertiary care center in Nepal with a large sample size (n=2153) showed a high prevalence of isolates with overlapping resistance to extended-spectrum cephalosporin and fluoroquinolone in both inpatient and outpatient settings that is consistent with the hypothesis that these two groups of genes are co-spreading in Nepal [44]. TMQR and ESBL genes can be located in the same conjugative plasmid with other antimicrobial-resistant determinants, and this facilitates their simultaneous spread and contributes to the emergence of MDR [11]. Such co-localization implies that the use of either quinolones or β-lactams could also promote the selection of these strains as suggested in a study from Vietnam [45]. Considering that fluoroquinolone is typically avoided in children, high levels of fluoroquinolone resistance may be explained by the high prevalence of such strains, promoted by selective pressure in the community, and by the spread of strains with co-localization of TMQR and β-lactamases within the same conjugative plasmids.

TMQR genes seem to have community origin [42, 46], and several studies have shown that commensal gut microbiota frequently harbors these genes [46, 47], as do isolates from other body surfaces [48]. With the growing appreciation of the involvement of the gut microbiome [49] and urinary microbiome in causing UTI [50], the detection and characterization of TMQR genes from the microbiome of these niches could be a future investigation at our institution. Characterization of the genetic background of TMQR (such as TMQR copy number, and expression level), conjugation experiments, phylogrouping, and MLST could be another aspect of focus for further research. The lack of data on whether the patients had consumed antimicrobials prior to hospital visits is a limitation of this study. In addition, we have not characterized other mechanisms of quinolone resistance, such as chromosomal efflux pumps, permeability alterations, and the role of biofilms.

Conclusions

Our study demonstrates alarmingly high levels of FQ resistance among *E. coli* and *K. pneumoniae* causing UTI in Nepalese children indicating the presence of high selective pressure in the community to promote their resistance. High prevalence and diversity in combinations of TMQR genes among quinolone-resistant *E. coli* and *K.*

pneumoniae suggest an important role of these genes in the emergence of Q/FQ resistance. Also, the findings of this study highlight the dissemination of TMQR along with β -lactamases among the pediatric population in Nepal, amplifying multidrug resistance. The increase in FQ resistance is a challenge for the management of UTIs. Comprehensive prospective surveillance of antimicrobial resistance in these common pathogens will be necessary to understand the origin and spread of TMQR genes and to devise strategies to mitigate the emergence of further resistance.

List of abbreviations

UTI	Urinary tract infection
DNA	Deoxyribonucleic acid
QRDR	Quinolone resistance-determining region
ICU	Intensive care unit
CFU	Colony forming unit
TMQR	Transferable mechanisms of quinolone resistance
WBC	White blood cells
HPF	High-power field
CLSI	Clinical Laboratory Standards Institute
ESBL	Extended-spectrum β -lactamase

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12887-023-04279-5>.

Supplementary Material 1
Supplementary Material 2
Supplementary Material 3

Acknowledgements

We would like to thank Mr. Anil Rajbhandari for supporting this project and the laboratory staff of Siddhi Memorial Hospital for providing the study isolates. We would also like to extend our special thanks to Associate Professor Chanwit Tribuddharat, Faculty of Medicine Siriraj Hospital, Mahidol University, for kindly sending us the positive controls for *qnrA*.

Author contributions

RKS and AT conceptualized the study. RKS, DS, and SP designed the study. RKS and AT performed the laboratory work. AA, RA, SP, and NS performed the literature review and assisted in standard operating procedure (SOP) preparation, data collection, and analysis. RKS prepared the first draft of the manuscript. CMP and BGD reviewed, edited, and revised the manuscript. All authors contributed to the preparation of the manuscript.

Funding

No external funding was received for this project.

Data Availability

The datasets generated and/or analysed during the current study are available in the GenBank repository (<https://www.ncbi.nlm.nih.gov/genbank/>), accession numbers OR271074 to OR271143.

Declarations

Competing interests

The authors declare no competing interests.

Ethics approval and consent to participate

The study protocol was approved by the ethical review committee of the Nepal Health Research Council (NHRC) (Reg. no. 100/2020). The ethics committee of NHRC waived the need for informed consent due to the

retrospective nature of this study. The bacterial isolates were obtained as a part of the hospital's routine patient diagnosis, and the current work was conducted as a part of the hospital's routine surveillance. Data used in this retrospective study were accessed from microbiology laboratory records which were devoid of any personal identifiers. Thus, individual written informed consent was not applicable and was waived by the ethical review committee of NHRC. All methods were carried out in compliance with National Ethical Guidelines for Health Research in Nepal 2022.

Consent for publication

Not applicable.

Author details

¹Siddhi Memorial Hospital, Bhaktapur, Nepal

²School of Tropical Medicine and Global Health (TMGH), Nagasaki University, Nagasaki, Japan

³Department of Respiratory Infections, Institute of Tropical Medicine, Nagasaki University, Nagasaki, Japan

⁴Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK

⁵Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK

Received: 22 February 2023 / Accepted: 28 August 2023

Published online: 13 September 2023

References

- Hooper DC, Jacoby GA. Topoisomerase inhibitors: Fluoroquinolone Mechanisms of Action and Resistance. *Cold Spring Harb Perspect Med*. 2016;6(9):a025320. <https://doi.org/10.1101/cshperspect.a025320>.
- Kim ES, Hooper DC. Clinical importance and epidemiology of Quinolone Resistance. *Infect Chemother*. 2014;46(4):226–38. <https://doi.org/10.3947/ic.2014.46.4.226>.
- World Health Organization Model List of Essential Medicines – 22nd List., 2021. Geneva: World Health Organization; 2021 (WHO/MHP/HPS/EML/2021.02). Licence: CC BY-NC-SA 3.0 IGO. <https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2021.02>.
- Fasugba O, Gardner A, Mitchell BG, Mnatzaganian G. Ciprofloxacin resistance in community- and hospital-acquired Escherichia coli urinary tract infections: a systematic review and meta-analysis of observational studies. *BMC Infect Dis*. 2015;15:545. <https://doi.org/10.1186/s12879-015-1282-4>.
- Ong A, Mahobia N, Browning D, Schembri M, Somani BK. Trends in antibiotic resistance for over 700,000 Escherichia coli positive urinary tract infections over six years (2014–2019) from a university teaching hospital. *Cent Eur J Urol*. 2021;74(2):249–54. <https://doi.org/10.5173/cej.2021.0053>.
- Durkin MJ, Jafarzadeh SR, Hsueh K, Sallah YH, Munshi KD, Henderson RR, et al. Outpatient antibiotic prescription Trends in the United States: A National Cohort Study. *Infect Control Hosp Epidemiol*. 2018;39(5):584–9. <https://doi.org/10.1017/ice.2018.26>.
- Williamson DA, Roos R, Verrall A, Smith A, Thomas MG. Trends, demographics and disparities in outpatient antibiotic consumption in New Zealand: a national study. *J Antimicrob Chemother*. 2016;71(12):3593–8. <https://doi.org/10.1093/jac/dkw345>.
- Drlica K, Hiasa H, Kerns R, Malik M, Mustaev A, Zhao X. Quinolones: action and resistance updated. *Curr Top Med Chem*. 2009;9(11):981–98. <https://doi.org/10.2174/156802609789630947>.
- Ruiz J. Mechanisms of resistance to quinolones: target alterations, decreased accumulation and DNA gyrase protection. *J Antimicrob Chemother*. 2003;51(5):1109–17. <https://doi.org/10.1093/jac/dkg222>.
- Ruiz J. Transferable mechanisms of Quinolone Resistance from 1998 onward. *Clin Microbiol Rev*. 2019;32(4):e00007–19. <https://doi.org/10.1128/CMR.00007-19>.
- Rodríguez-Martínez JM, Machuca J, Cano ME, Calvo J, Martínez-Martínez L, Pascual A. Plasmid-mediated quinolone resistance: two decades on. *Drug Resist Updat*. 2016;29:13–29. <https://doi.org/10.1016/j.drug.2016.09.001>.
- Grady RW. Systemic quinolone antibiotics in children: a review of the use and safety. *Expert Opin Drug Saf*. 2005;4(4):623–30. <https://doi.org/10.1517/14740338.4.4.623>.

13. Bryce A, Hay AD, Lane IF, Thornton HV, Wootton M, Costelloe C. Global prevalence of antibiotic resistance in paediatric urinary tract infections caused by *Escherichia coli* and association with routine use of antibiotics in primary care: systematic review and meta-analysis. *BMJ*. 2016;352:i939. <https://doi.org/10.1136/bmj.i939>.
14. Nateghian AR, Karaji S, Zamani K. A decade of trends in the distribution and antimicrobial susceptibility of prevalent uropathogens among pediatric patients from Tehran, Iran during 2005–2016. *Asian J Urol*. 2021;8(3):253–9. <https://doi.org/10.1016/j.ajur.2020.05.008>.
15. Raya GB, Dhoubhadel BG, Shrestha D, Raya S, Laghu U, Shah A, et al. Multidrug-resistant and extended-spectrum beta-lactamase-producing uropathogens in children in Bhaktapur, Nepal. *Trop Med Health*. 2020;48:65. <https://doi.org/10.1186/s41182-020-00251-6>.
16. Parajuli NP, Maharjan P, Parajuli H, Joshi G, Paudel D, Sayami S, et al. High rates of multidrug resistance among uropathogenic *Escherichia coli* in children and analyses of ESBL producers from Nepal. *Antimicrob Resist Infect Control*. 2017;6:9. <https://doi.org/10.1186/s13756-016-0168-6>.
17. Shrestha LB, Baral R, Poudel P, Khanal B. Clinical, etiological and antimicrobial susceptibility profile of pediatric urinary tract infections in a tertiary care hospital of Nepal. *BMC Pediatr*. 2019;19(1):36. <https://doi.org/10.1186/s12887-019-1410-1>.
18. Thapaliya J, Khadka P, Thapa S, Gongal C. Enhanced quantitative urine culture technique, a slight modification, in detecting under-diagnosed pediatric urinary tract infection. *BMC Res Notes*. 2020;13(1):5. <https://doi.org/10.1186/s13104-019-4875-y>.
19. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing, Thirty first Informational Supplement in M100-S30, Wayne, PA, USA; 2020.
20. Clinical and Laboratory Standards Institute (CLSI). Methods for Dilution Antimicrobial Susceptibility Test for Bacteria That Grow Aerobically Document in M07-A9, 10th Edn. Wayne, PA, USA; 2015.
21. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. *Clin Microbiol Infect*. 2012;18(3):268–81. <https://doi.org/10.1111/j.1469-0691.2011.03570.x>.
22. Lewis JS, Herrera M, Wickes B, Patterson JE, Jorgensen JH. First Report of the emergence of CTX-M-Type extended-spectrum β -Lactamases (ESBLs) as the predominant ESBL isolated in a U.S. Health Care System. *Antimicrob Agents Chemother*. 2007;51(11):4015–21. <https://doi.org/10.1128/AAC.00576-07>.
23. Dallenne C, Da Costa A, Decré D, Favier C, Arlet G. Development of a set of multiplex PCR assays for the detection of genes encoding important β -lactamases in Enterobacteriaceae. *J Antimicrob Chemother*. 2010;65(3):490–5. <https://doi.org/10.1093/jac/dkp498>.
24. Poirel L, Walsh TR, Cuvillier V, Nordmann P. Multiplex PCR for detection of acquired carbapenemase genes. *Diagn Microbiol Infect Dis*. 2011;70(1):119–. <https://doi.org/10.1016/j.diagmicrobio.2010.12.002>. <https://doi.org/https://doi.org/> 23.
25. Ciesielczuk H, Hornsey M, Choi V, Woodford N, Wareham DW. Development and evaluation of a multiplex PCR for eight plasmid-mediated quinolone-resistance determinants. *J Med Microbiol*. 2013;62(Pt 12):1823–7. <https://doi.org/10.1099/jmm.0.064428-0>.
26. Weigel LM, Steward CD, Tenover FC. gyrA mutations associated with fluoroquinolone resistance in eight species of Enterobacteriaceae. *Antimicrob Agents Chemother*. 1998;42(10):2661–7. <https://doi.org/10.1128/AAC.42.10.2661>.
27. Vila J, Ruiz J, Goñi P, De Anta MT. Detection of mutations in parC in quinolone-resistant clinical isolates of *Escherichia coli*. *Antimicrob Agents Chemother*. 1996;40(2):491–3. <https://doi.org/10.1128/AAC.40.2.491>.
28. Paltansing S, Kraakman MEM, Ras JMC, Wessels E, Bernards AT. Characterization of fluoroquinolone and cephalosporin resistance mechanisms in Enterobacteriaceae isolated in a dutch teaching hospital reveals the presence of an *Escherichia coli* ST131 clone with a specific mutation in parE. *J Antimicrob Chemother*. 2012;68(1):40–5. <https://doi.org/10.1093/jac/dks365>.
29. Kim B, Seo M-R, Kim J, Kim Y, Wie S-H, Ki M, et al. Molecular epidemiology of ciprofloxacin-resistant *Escherichia coli* isolated from community-acquired urinary tract infections in Korea. *Infect Chemother*. 2020;52(2):194–203. <https://doi.org/10.3947/ic.2020.52.2.194>.
30. Kao C-Y, Wu H-M, Lin W-H, Tseng C-C, Yan J-J, Wang M-C, et al. Plasmid-mediated quinolone resistance determinants in quinolone-resistant *Escherichia coli* isolated from patients with bacteremia in a university hospital in Taiwan, 2001–2015. *Sci Rep*. 2016;6:32281. <https://doi.org/10.1038/srep32281>.
31. Zhao L, Zhang J, Zheng B, Wei Z, Shen P, Li S, et al. Molecular epidemiology and genetic diversity of fluoroquinolone-resistant *Escherichia coli* isolates from patients with community-onset infections in 30 Chinese County Hospitals. *J Clin Microbiol*. 2015;53(3):766–70. <https://doi.org/10.1128/JCM.02594-14>.
32. Azargun R, Soroush Barhaghi MH, Samadi Kafil H, Ahangar Oskouee M, Sadeghi V, Memar MY, et al. Frequency of DNA gyrase and topoisomerase IV mutations and plasmid-mediated quinolone resistance genes among *Escherichia coli* and *Klebsiella pneumoniae* isolated from urinary tract infections in Azerbaijan, Iran. *J Glob Antimicrob Resist*. 2019;17:39–43. <https://doi.org/10.1016/j.jgar.2018.11.003>.
33. Osei Sekyere J, Amoako DG. Genomic and phenotypic characterisation of fluoroquinolone resistance mechanisms in Enterobacteriaceae in Durban, South Africa. *PLoS ONE*. 2017;12(6):e0178888. <https://doi.org/10.1371/journal.pone.0178888>.
34. Kotb DN, Mahdy WK, Mahmoud MS, Khairy RMM. Impact of co-existence of PMQR genes and QRDR mutations on fluoroquinolone resistance in Enterobacteriaceae strains isolated from community and hospital acquired UTIs. *BMC Infect Dis*. 2019;19(1):979. <https://doi.org/10.1186/s12879-019-4606-y>.
35. Phan M-D, Peters KM, Fraga LA, Wallis SC, Hancock SJ, Nhu NTK, et al. Plasmid-mediated Ciprofloxacin Resistance imparts a selective advantage on *Escherichia coli* ST131. *Antimicrob Agents Chemother*. 2022;66(1):e02146–21. <https://doi.org/10.1128/AAC.02146-21>.
36. Azargun R, Sadeghi MR, Soroush Barhaghi MH, Samadi Kafil H, Yeganeh F, Ahangar Oskouee M, et al. The prevalence of plasmid-mediated quinolone resistance and ESBL-production in Enterobacteriaceae isolated from urinary tract infections. *Infect Drug Resist*. 2018;11:1007–14. <https://doi.org/10.2147/idr.S160720>.
37. Kim NH, Choi EH, Sung JY, Oh CE, Kim HB, Kim E-C, et al. Prevalence of plasmid-mediated Quinolone Resistance genes and Ciprofloxacin Resistance in Pediatric Bloodstream isolates of Enterobacteriaceae over a 9-Year period. *Jpn J Infect Dis*. 2013;66(2):151–4. <https://doi.org/10.7883/yoken.66.151>.
38. Araújo BF, Campos PAD, Royer S, Ferreira ML, Gonçalves IR, Batistão DWdF, et al. High frequency of the combined presence of QRDR mutations and PMQR determinants in multidrug-resistant *Klebsiella pneumoniae* and *Escherichia coli* isolates from nosocomial and community-acquired infections. *J Med Microbiol*. 2017;66(8):1144–50. <https://doi.org/10.1099/jmm.0.000551>.
39. Xue G, Li J, Feng Y, Xu W, Li S, Yan C, et al. High prevalence of plasmid-mediated Quinolone Resistance Determinants in *Escherichia coli* and *Klebsiella pneumoniae* isolates from Pediatric Patients in China. *Microb Drug Resist*. 2016;23(1):107–14. <https://doi.org/10.1089/mdr.2016.0004>.
40. Akgoz M, Akman I, Ates AB, Celik C, Keskin B, Ozmen Capin BB, et al. Plasmidic Fluoroquinolone Resistance genes in fluoroquinolone-resistant and/or extended Spectrum Beta-Lactamase-Producing *Escherichia coli* strains isolated from Pediatric and adult patients diagnosed with urinary tract infection. *Microb Drug Resist*. 2020;26(11):1334–41. <https://doi.org/10.1089/mdr.2020.0007>.
41. Zemmour A, Dali-Yahia R, Maatallah M, Saidi-Ouahrani N, Rahmani B, Benhamouche N, et al. High-risk clones of extended-spectrum β -lactamase-producing *Klebsiella pneumoniae* isolated from the University Hospital establishment of Oran, Algeria (2011–2012). *PLoS ONE*. 2021;16(7):e0254805. <https://doi.org/10.1371/journal.pone.0254805>.
42. Logan LK, Medernach RL, Rispens JR, Marshall SH, Hujer AM, Domitrovic TN, et al. Community Origins and Regional differences highlight risk of plasmid-mediated Fluoroquinolone resistant Enterobacteriaceae infections in children. *Pediatr Infect Dis J*. 2019;38(6):595–9. <https://doi.org/10.1097/INF.0000000000002205>.
43. Global antimicrobial resistance and use surveillance system (GLASS) report. 2022. Geneva: World Health Organization; 2022. Licence: CC BY-NC-SA 3.0 IGO. <https://www.who.int/publications/i/item/9789240062702>.
44. Manandhar S, Zellweger RM, Maharjan N, Dongol S, Prajapati KG, Thwaites G, et al. A high prevalence of multi-drug resistant gram-negative bacilli in a Nepali tertiary care hospital and associated widespread distribution of extended-spectrum beta-lactamase (ESBL) and carbapenemase-encoding genes. *Ann Clin Microbiol Antimicrob*. 2020;19(1):48. <https://doi.org/10.1186/s12941-020-00390-y>.
45. Vien LTM, Minh NNQ, Thuong TC, Khuong HD, Nga TVT, Thompson C, et al. The Co-Selection of Fluoroquinolone Resistance genes in the Gut Flora of Vietnamese Children. *PLoS ONE*. 2012;7(8):e42919. <https://doi.org/10.1371/journal.pone.0042919>.
46. Saksena R, Gaind R, Sinha A, Kothari C, Chellani H, Deb M. High prevalence of fluoroquinolone resistance amongst commensal flora of antibiotic naïve

- neonates: a study from India. *J Med Microbiol.* 2018;67(4):481–8. <https://doi.org/10.1099/jmm.0.000686>.
47. Li B, Chen Y, Wu Z, Zhao Z, Wu J, Cao Y. Prevalence of plasmid-mediated Quinolone Resistance genes among *Escherichia coli* in the gut of healthy people in Fuzhou, China. *Ann Lab Med.* 2018;38(4):384–6. <https://doi.org/10.3343/alm.2018.38.4.384>.
48. Minh Vien LT, Baker S, Phuong Thao LT, Phuong Tu LT, Thu Thuy C, Thu Nga TT, et al. High prevalence of plasmid-mediated quinolone resistance determinants in commensal members of the Enterobacteriaceae in Ho Chi Minh City, Vietnam. *J Med Microbiol.* 2009;58(Pt 12):1585–92. <https://doi.org/10.1099/jmm.0.010033-0>.
49. Magruder M, Sholi AN, Gong C, Zhang L, Edusei E, Huang J, et al. Gut uropathogen abundance is a risk factor for development of bacteriuria and urinary tract infection. *Nat Commun.* 2019;10(1):5521. <https://doi.org/10.1038/s41467-019-13467-w>.
50. Perez-Carrasco V, Soriano-Lerma A, Soriano M, Gutiérrez-Fernández J, García-Salcedo JA. Urinary microbiome: Yin and Yang of the urinary tract. *Front Cell Infect Microbiol.* 2021;11:617002. <https://doi.org/10.3389/fcimb.2021.617002>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.